Cytiva’s transcient cell line receives FDA AMT designation 

The US Food and Drug Administration (FDA) has given an advanced manufacturing technology (AMT) designation to Cytiva’s transient cell line, making it one of the first gene therapy manufacturing technologies to receive the designation.  

The ELEVECTA transient cell line for adeno-associated virus (AAV) manufacturing is said to reduce the formation and encapsidation of host cell DNA (hcDNA) by up to 99% compared to commercially available cell lines. 

Residual hcDNA is a critical quality attribute in AAV manufacturing that requires careful monitoring and control. Non-therapeutic DNA fragments, particularly those encapsidated within viral particles, represent a process‑related impurity that can impact product consistency and purity. However, once hcDNA is packaged inside the capsid, it cannot be effectively removed through downstream purification, making it a persistent challenge. 

The FDA’s AMT designation recognises drug manufacturing technologies that elevate the reliability, quality, and robustness of advanced therapeutics manufacturing.  

By enabling a streamlined Chemistry, Manufacturing, and Controls (CMC) review and frequent communication with the FDA, the AMT designation can help accelerate manufacturing-related development timelines and create a meaningful advantage through faster time to market. 

“The FDA’s AMT designation for the ELEVECTA transient cell line gives our customers a clearer and more predictable path to adopting advanced AAV manufacturing technologies,” Emmanuel Abate, President of Genomic Medicine at Cytiva. 

“The platform is designed to support a strong product quality profile, including significantly reduced levels of encapsidated host cell DNA. This establishes a clear path for AAV therapy development, helping teams mitigate risk and progress programmes with greater confidence.” 

The post Cytiva’s transcient cell line receives FDA AMT designation  appeared first on Drug Discovery World (DDW).